Skip to main content

Table 1 Baseline demographic characteristics

From: Differences in l-arginine metabolism and asthma morbidity among asthma patients with and without obstructive sleep apnea

 

No OSA (N = 230)

OSA (N = 92)

Total (N = 322)

Mean (SD)

   

Agea

44.3 (13.4)

53.2 (11.5)

46.9 (13.4)

BMIa

30.1 (8.6)

37.0 (9.2)

32.1 (9.3)

N (%)

   

Weight classa

   

Underweight

7 (3.1%)

0 (0.0%)

7 (2.2%)

Normal

55 (24.1%)

3 (3.3%)

58 (18.1%)

Overweight

71 (31.1%)

14 (15.2%)

85 (26.6%)

Obese

95 (41.7%)

75 (81.5%)

170 (53.1%)

Female sexa

192 (84.2%)

69 (75.0%)

261 (81.6%)

Racea

   

Black/African American

51(22.4%)

24 (26.1%)

75 (23.4%)

Hispanic/Latino

65 (28.5%)

33 (35.9%)

98 (30.6%)

White

82 (36.0%)

27 (29.3%)

109 (34.1%)

Other

30 (13.2%)

8 (8.7%)

38 (11.9%)

Recruitment siteb

   

New York

130 (56.8%)

59 (64.1%)

189 (58.9%)

Colorado

99 (43.2%)

33 (35.9%)

132 (41.1%)

Tobacco usec

   

Current

12 (5.3%)

3 (3.3%)

15 (4.7%)

Former

51 (22.4%)

27 (29.7%)

78 (24.5%)

Never

165 (72.4%)

61 (67.0%)

226 (70.8%)

Asthma onsetd

   

Early

88 (39.5%)

29 (31.9%)

117 (37.3%)

Late

135 (60.5%)

62 (68.1%)

197 (62.7%)

Maintenance inhalers

   

ICS

80 (34.8%)

23 (25.0%)

103 (32.0%)

ICS/LABA

102 (44.3%)

57 (62.0%)

159 (49.4%)

LAMA

16 (7.0%)

10 (10.9%)

26 (8.1%)

T2 inflammation

   

High

132 (57.4%)

44 (47.8%)

176 (54.7%)

Low

98 (42.6%)

48 (52.2%)

146 (45.3%)

  1. ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist
  2. aN = 320
  3. bN = 321
  4. cN = 319
  5. dN = 314